ACCESS4Me™ for ROLVEDON® (eflapegrastim-xnst) injection is now digitally integrated with AssistPoint®

Assertio is the latest life science company to partner with Annexus Health. Healthcare organizations can now enroll eligible patients into ACCESS4ME™ for ROLVEDON® (eflapegrastim-xnst) injection directly within the AssistPoint software platform for the following: 

  • Benefits Verification  
  • Prior Authorization  
  • Claims & Appeals Support  
  • Copay Assistance 
  • Patient Assistance Program (PAP) 
  • Independent Charitable Foundation Information 

To learn more about ACCESS4Me, please visit

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. They have a robust portfolio of branded prescription neurology, inflammation, and pain medications. The company has grown through business development including acquisitions, licensing, and mergers, and they leverage their commercial excellence to be the partner of choice.